REFERENCES
[1] Camm CF, Camm AJ. Atrial Fibrillation and Anticoagulation in
Hypertrophic Cardiomyopathy. Arrhythmia & electrophysiology review.
2017;6:63-8.
[2] Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ.
Impact of atrial fibrillation on the clinical course of hypertrophic
cardiomyopathy. Circulation. 2001;104:2517-24.
[3] Tsuda T, Hayashi K, Fujino N, Konno T, Tada H, Nomura A, et al.
Effect of hypertrophic cardiomyopathy on the prediction of
thromboembolism in patients with nonvalvular atrial fibrillation. Heart
Rhythm. 2019;16:829-37.
[4] Maron BJ, Olivotto I, Bellone P, Conte MR, Cecchi F, Flygenring
BP, et al. Clinical profile of stroke in 900 patients with hypertrophic
cardiomyopathy. J Am Coll Cardiol. 2002;39:301-7.
[5] Maron BJ, Haas TS, Maron MS, Lesser JR, Browning JA, Chan RH, et
al. Left atrial remodeling in hypertrophic cardiomyopathy and
susceptibility markers for atrial fibrillation identified by
cardiovascular magnetic resonance. Am J Cardiol. 2014;113:1394-400.
[6] Cochet H, Morlon L, Verge MP, Salel M, Camaioni C, Reynaud A, et
al. Predictors of future onset of atrial fibrillation in hypertrophic
cardiomyopathy. Arch Cardiovasc Dis. 2018;111:591-600.
[7] Tuluce K, Yakar Tuluce S, Kahya Eren N, Kocabas U, Akyildiz
Akcay F, Gunduz R, et al. Predictors of Future Atrial Fibrillation
Development in Patients with Hypertrophic Cardiomyopathy: A Prospective
Follow-Up Study. Echocardiography. 2016;33:379-85.
[8] Schnabel RB, Sullivan LM, Levy D, Pencina MJ, Massaro JM,
D’Agostino RB, Sr., et al. Development of a risk score for atrial
fibrillation (Framingham Heart Study): a community-based cohort study.
Lancet. 2009;373:739-45.
[9] Alonso A, Krijthe BP, Aspelund T, Stepas KA, Pencina MJ, Moser
CB, et al. Simple risk model predicts incidence of atrial fibrillation
in a racially and geographically diverse population: the CHARGE-AF
consortium. J Am Heart Assoc. 2013;2:e000102.
[10] Chamberlain AM, Agarwal SK, Folsom AR, Soliman EZ, Chambless
LE, Crow R, et al. A clinical risk score for atrial fibrillation in a
biracial prospective cohort (from the Atherosclerosis Risk in
Communities [ARIC] study). Am J Cardiol. 2011;107:85-91.
[11] Bundy JD, Heckbert SR, Chen LY, Lloyd-Jones DM, Greenland P.
Evaluation of Risk Prediction Models of Atrial Fibrillation (from the
Multi-Ethnic Study of Atherosclerosis [MESA]). Am J Cardiol. 2019.
[12] Harris TB, Launer LJ, Eiriksdottir G, Kjartansson O, Jonsson
PV, Sigurdsson G, et al. Age, Gene/Environment Susceptibility-Reykjavik
Study: multidisciplinary applied phenomics. Am J Epidemiol.
2007;165:1076-87.
[13] Ikram MA, Brusselle GGO, Murad SD, van Duijn CM, Franco OH,
Goedegebure A, et al. The Rotterdam Study: 2018 update on objectives,
design and main results. Eur J Epidemiol. 2017;32:807-50.
[14] Bhattacharya M, Lu DY, Kudchadkar SM, Greenland GV, Lingamaneni
P, Corona-Villalobos CP, et al. Identifying Ventricular Arrhythmias and
Their Predictors by Applying Machine Learning Methods to Electronic
Health Records in Patients With Hypertrophic Cardiomyopathy
(HCM-VAr-Risk Model). Am J Cardiol. 2019;123:1681-9.
[15] Lu DY, Ventoulis I, Liu H, Kudchadkar SM, Greenland GV, Yalcin
H, et al. Sex-specific cardiac phenotype and clinical outcomes in
patients with hypertrophic cardiomyopathy. Am Heart J. 2019;219:58-69.
[16] Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, et
al. 2011 ACCF/AHA guideline for the diagnosis and treatment of
hypertrophic cardiomyopathy: a report of the American College of
Cardiology Foundation/American Heart Association Task Force on Practice
Guidelines. Circulation. 2011;124:e783-831.
[17] Sankaranarayanan R, E JF, C JG. Mimics of Hypertrophic
Cardiomyopathy - Diagnostic Clues to Aid Early Identification of
Phenocopies. Arrhythm Electrophysiol Rev. 2013;2:36-40.
[18] January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE,
Cleveland JC, Jr., et al. 2014 AHA/ACC/HRS guideline for the management
of patients with atrial fibrillation: executive summary: a report of the
American College of Cardiology/American Heart Association Task Force on
practice guidelines and the Heart Rhythm Society. Circulation.
2014;130:2071-104.
[19] January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE,
Cleveland JC, Jr., et al. 2014 AHA/ACC/HRS guideline for the management
of patients with atrial fibrillation: a report of the American College
of Cardiology/American Heart Association Task Force on practice
guidelines and the Heart Rhythm Society. Circulation. 2014;130:e199-267.
[20] Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande
L, et al. Recommendations for cardiac chamber quantification by
echocardiography in adults: an update from the American Society of
Echocardiography and the European Association of Cardiovascular Imaging.
J Am Soc Echocardiogr. 2015;28:1-39 e14.
[21] Liu H, Pozios I, Haileselassie B, Nowbar A, Sorensen LL,
Phillip S, et al. Role of Global Longitudinal Strain in Predicting
Outcomes in Hypertrophic Cardiomyopathy. Am J Cardiol. 2017;120:670-5.
[22] Bravo PE, Zimmerman SL, Luo HC, Pozios I, Rajaram M, Pinheiro
A, et al. Relationship of delayed enhancement by magnetic resonance to
myocardial perfusion by positron emission tomography in hypertrophic
cardiomyopathy. Circ Cardiovasc Imaging. 2013;6:210-7.
[23] Yalcin H, Valenta I, Yalcin F, Corona-Villalobos C, Vasquez N,
Ra J, et al. Effect of Diffuse Subendocardial Hypoperfusion on Left
Ventricular Cavity Size by (13)N-Ammonia Perfusion PET in Patients With
Hypertrophic Cardiomyopathy. Am J Cardiol. 2016;118:1908-15.
[24] Murphy KP. Machine learning : a probabilistic perspective.
Cambridge, Mass.: MIT Press; 2012.
[25] Sokal RR, Rohlf FJ. Introduction to biostatistics. 2nd ed. New
York: Freeman; 1987.
[26] Welch BL. The Significance of the Difference Between Two Means
when the Population Variances are Unequal. Biometrika. 1938;29:350-62.
[27] Maron BJ, Wolfson JK, Epstein SE, Roberts WC. Intramural
(”small vessel”) coronary artery disease in hypertrophic cardiomyopathy.
J Am Coll Cardiol. 1986;8:545-57.
[28] Olsson U. Maximum likelihood estimation of the polychoric
correlation coefficient. Psychometrika. 1979;44:443-60.
[29] Fernandez-Ruiz I. Artificial intelligence to improve the
diagnosis of cardiovascular diseases. Nat Rev Cardiol. 2019;16:133.
[30] Zou L, Yu S, Meng T, Zhang Z, Liang X, Xie Y. A Technical
Review of Convolutional Neural Network-Based Mammographic Breast Cancer
Diagnosis. Comput Math Methods Med. 2019;2019:6509357.
[31] Daoud M, Mayo M. A survey of neural network-based cancer
prediction models from microarray data. Artif Intell Med.
2019;97:204-14.
[32] Abraham A, Pedregosa F, Eickenberg M, Gervais P, Mueller A,
Kossaifi J, et al. Machine learning for neuroimaging with scikit-learn.
Front Neuroinform. 2014;8:14.
[33] Tan AC, Gilbert D, Deville Y. Multi-class protein fold
classification using a new ensemble machine learning approach. Genome
Inform. 2003;14:206-17.
[34] Bhattacharya M, Jurkovitz C, Shatkay H. Assessing chronic
kidney disease from office visit records using hierarchical
meta-classification of an imbalanced dataset. 2017 IEEE International
Conference on Bioinformatics and Biomedicine (BIBM)2017. p. 663-70.
[35] Debonnaire P, Joyce E, Hiemstra Y, Mertens BJ, Atsma DE,
Schalij MJ, et al. Left Atrial Size and Function in Hypertrophic
Cardiomyopathy Patients and Risk of New-Onset Atrial Fibrillation. Circ
Arrhythm Electrophysiol. 2017;10.
[36] Guttmann OP, Rahman MS, O’Mahony C, Anastasakis A, Elliott PM.
Atrial fibrillation and thromboembolism in patients with hypertrophic
cardiomyopathy: systematic review. Heart. 2014;100:465-72.
[37] Al’Aref SJ, Anchouche K, Singh G, Slomka PJ, Kolli KK, Kumar A,
et al. Clinical applications of machine learning in cardiovascular
disease and its relevance to cardiac imaging. Eur Heart J.
2019;40:1975-86.
[38] Vallee A, Cinaud A, Blachier V, Lelong H, Safar ME, Blacher J.
Coronary heart disease diagnosis by artificial neural networks including
aortic pulse wave velocity index and clinical parameters. J Hypertens.
2019;37:1682-8.
[39] Tsang TS, Gersh BJ, Appleton CP, Tajik AJ, Barnes ME, Bailey
KR, et al. Left ventricular diastolic dysfunction as a predictor of the
first diagnosed nonvalvular atrial fibrillation in 840 elderly men and
women. J Am Coll Cardiol. 2002;40:1636-44.
[40] Patton KK, Ellinor PT, Heckbert SR, Christenson RH, DeFilippi
C, Gottdiener JS, et al. N-terminal pro-B-type natriuretic peptide is a
major predictor of the development of atrial fibrillation: the
Cardiovascular Health Study. Circulation. 2009;120:1768-74.
[41] Schotten U, Neuberger HR, Allessie MA. The role of atrial
dilatation in the domestication of atrial fibrillation. Prog Biophys Mol
Biol. 2003;82:151-62.
[42] Tsang TS, Barnes ME, Gersh BJ, Bailey KR, Seward JB. Risks for
atrial fibrillation and congestive heart failure in patients
>/=65 years of age with abnormal left ventricular diastolic
relaxation. Am J Cardiol. 2004;93:54-8.
[43] Rosenberg MA, Gottdiener JS, Heckbert SR, Mukamal KJ.
Echocardiographic diastolic parameters and risk of atrial fibrillation:
the Cardiovascular Health Study. Eur Heart J. 2012;33:904-12.
[44] Tani T, Tanabe K, Ono M, Yamaguchi K, Okada M, Sumida T, et al.
Left atrial volume and the risk of paroxysmal atrial fibrillation in
patients with hypertrophic cardiomyopathy. J Am Soc Echocardiogr.
2004;17:644-8.
[45] Spirito P, Autore C, Formisano F, Assenza GE, Biagini E, Haas
TS, et al. Risk of sudden death and outcome in patients with
hypertrophic cardiomyopathy with benign presentation and without risk
factors. Am J Cardiol. 2014;113:1550-5.
[46] Yang WI, Shim CY, Kim YJ, Kim SA, Rhee SJ, Choi EY, et al. Left
atrial volume index: a predictor of adverse outcome in patients with
hypertrophic cardiomyopathy. J Am Soc Echocardiogr. 2009;22:1338-43.
[47] Tian T, Wang Y, Sun K, Wang J, Zou Y, Zhang W, et al. Clinical
profile and prognostic significance of atrial fibrillation in
hypertrophic cardiomyopathy. Cardiology. 2013;126:258-64.
[48] Losi MA, Betocchi S, Aversa M, Lombardi R, Miranda M,
D’Alessandro G, et al. Determinants of atrial fibrillation development
in patients with hypertrophic cardiomyopathy. Am J Cardiol.
2004;94:895-900.
[49] Kotecha D, Piccini JP. Atrial fibrillation in heart failure:
what should we do? Eur Heart J. 2015;36:3250-7.
[50] Nagueh SF, Lakkis NM, Middleton KJ, Spencer WH, 3rd, Zoghbi WA,
Quinones MA. Doppler estimation of left ventricular filling pressures in
patients with hypertrophic cardiomyopathy. Circulation. 1999;99:254-61.
[51] Rosenberg MA, Manning WJ. Diastolic dysfunction and risk of
atrial fibrillation: a mechanistic appraisal. Circulation.
2012;126:2353-62.
[52] Jons C, Joergensen RM, Hassager C, Gang UJ, Dixen U, Johannesen
A, et al. Diastolic dysfunction predicts new-onset atrial fibrillation
and cardiovascular events in patients with acute myocardial infarction
and depressed left ventricular systolic function: a CARISMA substudy.
Eur J Echocardiogr. 2010;11:602-7.
[53] Pujadas S, Vidal-Perez R, Hidalgo A, Leta R, Carreras F, Barros
A, et al. Correlation between myocardial fibrosis and the occurrence of
atrial fibrillation in hypertrophic cardiomyopathy: a cardiac magnetic
resonance imaging study. Eur J Radiol. 2010;75:e88-91.
[54] Yamaji K, Fujimoto S, Yutani C, Ikeda Y, Mizuno R, Hashimoto T,
et al. Does the progression of myocardial fibrosis lead to atrial
fibrillation in patients with hypertrophic cardiomyopathy? Cardiovasc
Pathol. 2001;10:297-303.
[55] Papavassiliu T, Germans T, Fluchter S, Doesch C, Suriyakamar A,
Haghi D, et al. CMR findings in patients with hypertrophic
cardiomyopathy and atrial fibrillation. J Cardiovasc Magn Reson.
2009;11:34.
[56] Sivalokanathan S, Zghaib T, Greenland GV, Vasquez N, Kudchadkar
SM, Kontari E, et al. Hypertrophic Cardiomyopathy Patients With
Paroxysmal Atrial Fibrillation Have a High Burden of Left Atrial
Fibrosis by Cardiac Magnetic Resonance Imaging. JACC Clin
Electrophysiol. 2019;5:364-75.
[57] Azarbal F, Singh M, Finocchiaro G, Le VV, Schnittger I, Wang P,
et al. Exercise capacity and paroxysmal atrial fibrillation in patients
with hypertrophic cardiomyopathy. Heart. 2014;100:624-30.
[58] Vasquez N, Ostrander BT, Lu DY, Ventoulis I, Haileselassie B,
Goyal S, et al. Low Left Atrial Strain Is Associated With Adverse
Outcomes in Hypertrophic Cardiomyopathy Patients. J Am Soc Echocardiogr.
2019;32:593-603 e1.
[59] Dickinson MG, Lam CS, Rienstra M, Vonck TE, Hummel YM, Voors
AA, et al. Atrial fibrillation modifies the association between
pulmonary artery wedge pressure and left ventricular end-diastolic
pressure. Eur J Heart Fail. 2017;19:1483-90.
[60] Luo HC, Dimaano VL, Kembro JM, Hilser A, Hurtado-de-Mendoza D,
Pozios I, et al. Exercise heart rates in patients with hypertrophic
cardiomyopathy. Am J Cardiol. 2015;115:1144-50.
[61] Maron BJ, Rowin EJ, Casey SA, Haas TS, Chan RH, Udelson JE, et
al. Risk stratification and outcome of patients with hypertrophic
cardiomyopathy >=60 years of age. Circulation.
2013;127:585-93.
[62] Bravo PE, Pinheiro A, Higuchi T, Rischpler C, Merrill J,
Santaularia-Tomas M, et al. PET/CT assessment of symptomatic individuals
with obstructive and nonobstructive hypertrophic cardiomyopathy. J Nucl
Med. 2012;53:407-14.
[63] Hurtado-de-Mendoza D, Corona-Villalobos CP, Pozios I, Gonzales
J, Soleimanifard Y, Sivalokanathan S, et al. Diffuse interstitial
fibrosis assessed by cardiac magnetic resonance is associated with
dispersion of ventricular repolarization in patients with hypertrophic
cardiomyopathy. J Arrhythm. 2017;33:201-7.
[64] Kobayashi T, Popovic Z, Bhonsale A, Smedira NG, Tan C,
Rodriguez ER, et al. Association between septal strain rate and
histopathology in symptomatic hypertrophic cardiomyopathy patients
undergoing septal myectomy. Am Heart J. 2013;166:503-11.
[65] Spirito P, Watson RM, Maron BJ. Relation between extent of left
ventricular hypertrophy and occurrence of ventricular tachycardia in
hypertrophic cardiomyopathy. Am J Cardiol. 1987;60:1137-42.
[66] D’Amato R, Tomberli B, Castelli G, Spoladore R, Girolami F,
Fornaro A, et al. Prognostic value of N-terminal pro-brain natriuretic
Peptide in outpatients with hypertrophic cardiomyopathy. Am J Cardiol.
2013;112:1190-6.
[67] Gruver EJ, Fatkin D, Dodds GA, Kisslo J, Maron BJ, Seidman JG,
et al. Familial hypertrophic cardiomyopathy and atrial fibrillation
caused by Arg663His beta-cardiac myosin heavy chain mutation. Am J
Cardiol. 1999;83:13H-8H.
[68] Ogimoto A, Hamada M, Nakura J, Miki T, Hiwada K. Relation
between angiotensin-converting enzyme II genotype and atrial
fibrillation in Japanese patients with hypertrophic cardiomyopathy. J
Hum Genet. 2002;47:184-9.
[69] Bongini C, Ferrantini C, Girolami F, Coppini R, Arretini A,
Targetti M, et al. Impact of Genotype on the Occurrence of Atrial
Fibrillation in Patients With Hypertrophic Cardiomyopathy. Am J Cardiol.
2016;117:1151-9.